Overview A Safety PK/PD Study of SLV337 in Patients With Type 2 Diabetes Status: Completed Trial end date: 2010-12-01 Target enrollment: Participant gender: Summary The purpose of this study is to assess safety, tolerability, pharmacokinetics and pharmacodynamics of SLV337 in patients with type 2 diabetes Phase: Phase 2 Details Lead Sponsor: Abbott ProductsCollaborator: Quintiles, Inc.